AI Engines For more Details: Perplexity Kagi Labs You
Parkinson's Disease: Ethopropazine hydrochloride is used to alleviate some of the symptoms associated with Parkinson's disease, such as tremors, rigidity, and bradykinesia (slowness of movement). It works by acting as a centrally acting anticholinergic agent, blocking the action of acetylcholine in the central nervous system, which helps to rebalance the levels of neurotransmitters.
Extrapyramidal Symptoms: Ethopropazine hydrochloride may also be prescribed to manage extrapyramidal symptoms (EPS) caused by certain medications, particularly antipsychotics. EPS can include dystonia, akathisia, parkinsonism, and tardive dyskinesia. Ethopropazine helps alleviate these symptoms by reducing abnormal muscle contractions and movements.
Muscle Relaxation: The medication's anticholinergic properties contribute to muscle relaxation, which can help reduce muscle stiffness and spasms associated with Parkinson's disease and other movement disorders.
Adjunctive Therapy: Ethopropazine hydrochloride is often used in combination with other medications for Parkinson's disease, such as levodopa/carbidopa or dopamine agonists, to enhance therapeutic effects and improve motor function.
Dosage and Administration: The dosage of ethopropazine hydrochloride may vary depending on the individual patient's response and tolerance. It is typically administered orally in tablet form, with dosing frequency determined by the prescribing healthcare provider.
Side Effects: Common side effects of ethopropazine hydrochloride may include dry mouth, blurred vision, urinary retention, constipation, drowsiness, dizziness, and confusion. These side effects are often dose-related and may improve with dosage adjustments or discontinuation of the medication.
Contraindications: Ethopropazine hydrochloride is contraindicated in individuals with narrow-angle glaucoma, severe gastrointestinal obstruction, urinary retention, and certain other medical conditions. It should be used with caution in elderly patients and those with preexisting cognitive impairment.
Drug Interactions: Ethopropazine hydrochloride may interact with other medications, including anticholinergic agents, antidepressants, antipsychotics, and certain antibiotics. Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
Monitoring: Regular monitoring by a healthcare professional is essential to assess treatment efficacy, monitor for adverse effects, and adjust medication dosage as needed.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 3.6 | 0.6 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 1.1 | 1 |
| Allergies | 5.9 | 2.9 | 1.03 |
| Allergy to milk products | 1.8 | 1.3 | 0.38 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 6.8 | 6.1 | 0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 1 | 2 |
| Ankylosing spondylitis | 3.9 | 1.3 | 2 |
| Anorexia Nervosa | 1.2 | 3 | -1.5 |
| Antiphospholipid syndrome (APS) | 1.2 | 0.3 | 3 |
| Asthma | 3.8 | 2.5 | 0.52 |
| Atherosclerosis | 1.6 | 2.7 | -0.69 |
| Atrial fibrillation | 3.2 | 2.8 | 0.14 |
| Autism | 9 | 8.3 | 0.08 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 2.2 | 1.7 | 0.29 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 0.4 | 0.3 | 0.33 |
| Cancer (General) | 0.6 | 0.6 | 0 |
| Carcinoma | 3.5 | 1.7 | 1.06 |
| Celiac Disease | 2.7 | 2.8 | -0.04 |
| Cerebral Palsy | 1.3 | 1.3 | 0 |
| Chronic Fatigue Syndrome | 4.2 | 5.8 | -0.38 |
| Chronic Kidney Disease | 3.8 | 2.8 | 0.36 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.7 | 0 |
| Chronic Urticaria (Hives) | 1.2 | 1.8 | -0.5 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.3 | 0.08 |
| Cognitive Function | 2.5 | 1.1 | 1.27 |
| Colorectal Cancer | 8.3 | 2.6 | 2.19 |
| Constipation | 2.1 | 1.2 | 0.75 |
| Coronary artery disease | 2.3 | 3 | -0.3 |
| COVID-19 | 8 | 10.5 | -0.31 |
| Crohn's Disease | 7.7 | 5.3 | 0.45 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1 | -0.43 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 3 | 1.4 | 1.14 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 9.5 | 8.3 | 0.14 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.6 | 1.4 | 0.14 |
| Endometriosis | 2.1 | 2.1 | 0 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.7 | 2.5 | 0.08 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 2 | 2.6 | -0.3 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 3.8 | 0.29 |
| gallstone disease (gsd) | 2.9 | 1 | 1.9 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.9 | 0.67 |
| Generalized anxiety disorder | 2.9 | 1.9 | 0.53 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.8 | 1.4 | 1 |
| Graves' disease | 1.6 | 2.4 | -0.5 |
| Gulf War Syndrome | 0.7 | 2.3 | -2.29 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.6 | 1.3 | 1 |
| Heart Failure | 3.4 | 2.1 | 0.62 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.6 | 0.3 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.6 | -0.5 |
| hyperglycemia | 1.9 | 1.9 | 0 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.3 | 4.2 | 0.02 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 1.9 | 0.6 | 2.17 |
| IgA nephropathy (IgAN) | 1.6 | 3.9 | -1.44 |
| Inflammatory Bowel Disease | 7.6 | 8.3 | -0.09 |
| Insomnia | 2.1 | 3.5 | -0.67 |
| Intelligence | 1.3 | 0.6 | 1.17 |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 6.5 | 5.9 | 0.1 |
| ischemic stroke | 2.3 | 1.7 | 0.35 |
| Liver Cirrhosis | 6.1 | 4 | 0.52 |
| Long COVID | 7.1 | 5.7 | 0.25 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1 | 0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.5 | 1.2 | -1.4 |
| ME/CFS without IBS | 1.5 | 0.9 | 0.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 1 | -0.11 |
| Metabolic Syndrome | 7.2 | 6 | 0.2 |
| Mood Disorders | 9.5 | 7.7 | 0.23 |
| multiple chemical sensitivity [MCS] | 1.6 | 0.1 | 15 |
| Multiple Sclerosis | 5.8 | 4.8 | 0.21 |
| Multiple system atrophy (MSA) | 1.3 | 0.4 | 2.25 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 1.2 | 2.7 | -1.25 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 4.2 | 0.02 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.3 | 4.33 |
| Obesity | 9.2 | 6.7 | 0.37 |
| obsessive-compulsive disorder | 5.7 | 3.2 | 0.78 |
| Osteoarthritis | 2.4 | 1.4 | 0.71 |
| Osteoporosis | 2.4 | 1.3 | 0.85 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 8.1 | 5.4 | 0.5 |
| Polycystic ovary syndrome | 6.3 | 2.8 | 1.25 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.6 | 1.2 | -1 |
| Primary sclerosing cholangitis | 1.6 | 2.6 | -0.63 |
| Psoriasis | 2.7 | 4 | -0.48 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.3 | 3.3 | 0.91 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 5.3 | 3 | 0.77 |
| scoliosis | 0.4 | 0.7 | -0.75 |
| Sjögren syndrome | 2.7 | 1.7 | 0.59 |
| Sleep Apnea | 1 | 1.8 | -0.8 |
| Slow gastric motility / Gastroparesis | 1 | 1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 1.8 | 2.9 | -0.61 |
| Systemic Lupus Erythematosus | 4.2 | 1.6 | 1.63 |
| Tic Disorder | 1.5 | 0.9 | 0.67 |
| Tourette syndrome | 0.8 | 0.3 | 1.67 |
| Type 1 Diabetes | 5.5 | 2.3 | 1.39 |
| Type 2 Diabetes | 8.2 | 6.7 | 0.22 |
| Ulcerative colitis | 3.7 | 7.7 | -1.08 |
| Unhealthy Ageing | 4.2 | 2.6 | 0.62 |
| Vitiligo | 2.2 | 1.5 | 0.47 |
